JP2004507531A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507531A5 JP2004507531A5 JP2002523479A JP2002523479A JP2004507531A5 JP 2004507531 A5 JP2004507531 A5 JP 2004507531A5 JP 2002523479 A JP2002523479 A JP 2002523479A JP 2002523479 A JP2002523479 A JP 2002523479A JP 2004507531 A5 JP2004507531 A5 JP 2004507531A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- alkyl
- compound
- compound according
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 72
- 125000004432 carbon atom Chemical group C* 0.000 description 61
- 125000000217 alkyl group Chemical group 0.000 description 44
- 150000003839 salts Chemical class 0.000 description 14
- -1 1-imidazolyl Chemical group 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 229910052736 halogen Chemical group 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 125000002541 furyl group Chemical group 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000001624 naphthyl group Chemical group 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- JBKIUXYXZUSWPS-UHFFFAOYSA-N 2-[4-(8,8-dimethyl-5-oxo-6,7-dihydronaphthalene-2-carbonyl)oxyphenyl]acetic acid Chemical compound C1=C2C(C)(C)CCC(=O)C2=CC=C1C(=O)OC1=CC=C(CC(O)=O)C=C1 JBKIUXYXZUSWPS-UHFFFAOYSA-N 0.000 description 1
- ITXFQVKXIVKNHH-UHFFFAOYSA-N 2-[4-[2-(2,2,4,4-tetramethyl-3h-chromen-6-yl)ethynyl]phenyl]acetic acid Chemical compound C=1C=C2OC(C)(C)CC(C)(C)C2=CC=1C#CC1=CC=C(CC(O)=O)C=C1 ITXFQVKXIVKNHH-UHFFFAOYSA-N 0.000 description 1
- DGFTWCCCWFYBFB-UHFFFAOYSA-N 2-[4-[2-(5-imidazol-1-yl-8,8-dimethyl-6,7-dihydro-5h-naphthalen-2-yl)ethynyl]phenyl]acetic acid Chemical compound C1=C2C(C)(C)CCC(N3C=NC=C3)C2=CC=C1C#CC1=CC=C(CC(O)=O)C=C1 DGFTWCCCWFYBFB-UHFFFAOYSA-N 0.000 description 1
- LWCBOTGILHXRHK-UHFFFAOYSA-N 2-[4-[2-(8,8-dimethyl-5-oxo-6,7-dihydronaphthalen-2-yl)ethynyl]-2-fluorophenyl]acetic acid Chemical compound C1=C2C(C)(C)CCC(=O)C2=CC=C1C#CC1=CC=C(CC(O)=O)C(F)=C1 LWCBOTGILHXRHK-UHFFFAOYSA-N 0.000 description 1
- FKURZNWAFOUMKK-UHFFFAOYSA-N 2-[4-[2-(8-cyclopropyl-2,2,4,4-tetramethyl-3h-chromen-6-yl)ethynyl]phenyl]acetic acid Chemical compound C=12OC(C)(C)CC(C)(C)C2=CC(C#CC=2C=CC(CC(O)=O)=CC=2)=CC=1C1CC1 FKURZNWAFOUMKK-UHFFFAOYSA-N 0.000 description 1
- UBXQMNPDZOGDSY-UHFFFAOYSA-N 2-[4-[2-(8-ethyl-2,2,4,4-tetramethyl-3h-chromen-6-yl)ethynyl]phenyl]acetic acid Chemical compound C=1C(C(CC(C)(C)O2)(C)C)=C2C(CC)=CC=1C#CC1=CC=C(CC(O)=O)C=C1 UBXQMNPDZOGDSY-UHFFFAOYSA-N 0.000 description 1
- ZFDGDSDFJCLIBX-UHFFFAOYSA-N 2-[4-[2-[5-[cyclopropyl(methyl)amino]-8,8-dimethyl-6,7-dihydro-5h-naphthalen-2-yl]ethynyl]-2-fluorophenyl]acetic acid Chemical compound C1CC(C)(C)C2=CC(C#CC=3C=C(F)C(CC(O)=O)=CC=3)=CC=C2C1N(C)C1CC1 ZFDGDSDFJCLIBX-UHFFFAOYSA-N 0.000 description 1
- WNJLJQKQEKVIJT-UHFFFAOYSA-N 2-fluoro-4-[2-(2,2,4,4-tetramethyl-3h-chromen-6-yl)ethynyl]benzoic acid Chemical compound C=1C=C2OC(C)(C)CC(C)(C)C2=CC=1C#CC1=CC=C(C(O)=O)C(F)=C1 WNJLJQKQEKVIJT-UHFFFAOYSA-N 0.000 description 1
- VSHLPGYGJSORKV-UHFFFAOYSA-N 4-[2-(8,8-dimethyl-5-oxo-6,7-dihydronaphthalen-2-yl)ethynyl]-2-fluorobenzoic acid Chemical compound C1=C2C(C)(C)CCC(=O)C2=CC=C1C#CC1=CC=C(C(O)=O)C(F)=C1 VSHLPGYGJSORKV-UHFFFAOYSA-N 0.000 description 1
- QELVCKRITXHFTQ-UHFFFAOYSA-N 4-[2-(8-cyclopropyl-2,2,4,4-tetramethyl-3h-chromen-6-yl)ethynyl]benzoic acid Chemical compound C=12OC(C)(C)CC(C)(C)C2=CC(C#CC=2C=CC(=CC=2)C(O)=O)=CC=1C1CC1 QELVCKRITXHFTQ-UHFFFAOYSA-N 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/651,004 US6369261B1 (en) | 2000-08-29 | 2000-08-29 | Compounds having activity as inhibitors of cytochrome P450RAI |
| US09/651,001 US6291677B1 (en) | 2000-08-29 | 2000-08-29 | Compounds having activity as inhibitors of cytochrome P450RAI |
| US09/651,564 US6380256B1 (en) | 2000-08-29 | 2000-08-29 | Compounds having activity as inhibitors of cytochrome P450RAI |
| US09/651,235 US6252090B1 (en) | 2000-08-29 | 2000-08-29 | Compounds having activity as inhibitors of cytochrome P450RAI |
| US09/651,234 US6387951B1 (en) | 2000-08-29 | 2000-08-29 | Compounds having activity as inhibitors of cytochrome P450RAI |
| US09/651,566 US6369225B1 (en) | 2000-08-29 | 2000-08-29 | Compounds having activity as inhibitors of cytochrome P450RAI |
| US09/651,003 US6303785B1 (en) | 2000-08-29 | 2000-08-29 | Compounds having activity as inhibitors of cytochrome P450RAI |
| PCT/US2001/025443 WO2002018361A2 (en) | 2000-08-29 | 2001-08-14 | Compounds having activity as inhibitors of cytochrome p450rai |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004507531A JP2004507531A (ja) | 2004-03-11 |
| JP2004507531A5 true JP2004507531A5 (enExample) | 2008-10-02 |
Family
ID=27569871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002523479A Pending JP2004507531A (ja) | 2000-08-29 | 2001-08-14 | シトクロムｐ４５０ｒａｉ阻害剤としての活性を有する化合物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1366036B1 (enExample) |
| JP (1) | JP2004507531A (enExample) |
| AT (1) | ATE315558T1 (enExample) |
| AU (2) | AU8647101A (enExample) |
| CA (1) | CA2420869A1 (enExample) |
| DE (1) | DE60116642T2 (enExample) |
| ES (1) | ES2256288T3 (enExample) |
| WO (1) | WO2002018361A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313107B1 (en) * | 2000-08-29 | 2001-11-06 | Allergan Sales, Inc. | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| JP5082033B2 (ja) | 2001-12-21 | 2012-11-28 | エグゼリクシス パテント カンパニー エルエルシー | Ｌｘｒのモジュレーター |
| US6740676B2 (en) * | 2002-03-19 | 2004-05-25 | Allergan, Inc. | 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| MXPA05003456A (es) | 2002-10-04 | 2005-07-05 | Millennium Pharm Inc | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias. |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| BRPI0413923A (pt) | 2003-08-29 | 2006-11-07 | Ono Pharmaceutical Co | composto capaz de ligar o receptor de s1p e uso farmacêutico do mesmo |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US7226951B2 (en) | 2003-12-17 | 2007-06-05 | Allergan, Inc. | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same |
| PL1826197T3 (pl) | 2004-12-13 | 2012-06-29 | Ono Pharmaceutical Co | Pochodna kwasu aminokarboksylowego i jej zastosowanie lecznicze |
| AU2005316739A1 (en) | 2004-12-13 | 2006-06-22 | Galileo Pharmaceuticals, Inc. | Spiro derivatives as lipoxygenase inhibitors |
| CA2598133A1 (en) | 2005-02-24 | 2006-08-31 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| CN103402986A (zh) | 2010-11-24 | 2013-11-20 | 阿勒根公司 | S1p受体的调节剂 |
| CA2848540A1 (en) | 2011-09-15 | 2013-03-21 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Therapeutic compounds |
| WO2015109318A2 (en) | 2014-01-17 | 2015-07-23 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Therapeutic methods |
| PT3204357T (pt) * | 2014-10-10 | 2022-03-31 | High Force Res Limited | Retinoides sintéticos fluorescentes |
| US10238655B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Dihydroindene and tetrahydronaphthalene compounds |
| US10238626B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| US10231947B2 (en) | 2017-01-23 | 2019-03-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Isochroman compounds and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3475305D1 (en) * | 1983-07-05 | 1988-12-29 | Pfizer | Carboxylic acid derivatives useful for inhibiting the degradation of cartilage |
| ZA875052B (en) * | 1986-07-11 | 1989-03-29 | Du Pont | Angiotensin ii receptor blocking imidazoles |
| US5089509A (en) * | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US5015658A (en) * | 1988-06-29 | 1991-05-14 | Allergan, Inc. | Thiochroman esters of phenols and terephthallates having retinoid-like activity |
| US5045551A (en) * | 1989-09-19 | 1991-09-03 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
| US5023341A (en) * | 1989-09-19 | 1991-06-11 | Allergan, Inc. | Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity |
| US5202471A (en) * | 1990-02-06 | 1993-04-13 | Allergan, Inc. | Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity |
| US5134159A (en) * | 1991-03-26 | 1992-07-28 | Allergan, Inc. | 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity |
| EP0800517A1 (en) * | 1994-12-29 | 1997-10-15 | Allergan | Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
| US5489584A (en) * | 1994-12-29 | 1996-02-06 | Allergan, Inc. | Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
| US5498795A (en) * | 1994-12-29 | 1996-03-12 | Allergan, Inc. | Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
| US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| US5739338A (en) * | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
-
2001
- 2001-08-14 ES ES01965920T patent/ES2256288T3/es not_active Expired - Lifetime
- 2001-08-14 DE DE60116642T patent/DE60116642T2/de not_active Expired - Fee Related
- 2001-08-14 AT AT01965920T patent/ATE315558T1/de not_active IP Right Cessation
- 2001-08-14 AU AU8647101A patent/AU8647101A/xx active Pending
- 2001-08-14 WO PCT/US2001/025443 patent/WO2002018361A2/en not_active Ceased
- 2001-08-14 EP EP01965920A patent/EP1366036B1/en not_active Expired - Lifetime
- 2001-08-14 JP JP2002523479A patent/JP2004507531A/ja active Pending
- 2001-08-14 CA CA002420869A patent/CA2420869A1/en not_active Abandoned
- 2001-08-14 AU AU2001286471A patent/AU2001286471B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004507531A5 (enExample) | ||
| JP2004509955A5 (enExample) | ||
| LTC2228064I2 (lt) | Farmacinė kompozicija, kurios sudėtyje yra glikopirolatas ir beta-2 adrenoceptorinis antagonistas | |
| HRP20160450T1 (hr) | Novi inhibitori reduktaze s-nitrozoglutationa | |
| RU2005135016A (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| CA2429844A1 (en) | Mch antagonists and their use in the treatment of obesity | |
| RU2002103603A (ru) | Фармацевтические композиции, содержащие ингибитор hmg редуктазы | |
| JP2007514773A5 (enExample) | ||
| JP2002541139A5 (enExample) | ||
| WO2006018718A3 (en) | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors | |
| HUT56365A (en) | Process for producing antimuscarine quinuclidine derivatives having bronchodilator effect and pharmaceutical compositions comprising same as active ingredient | |
| DE60125026D1 (de) | Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung | |
| JP2001526276A5 (enExample) | ||
| ATE556061T1 (de) | Therapeutisches oder prophylaktisches mittel gegen multiple sklerose | |
| JP2003523938A5 (enExample) | ||
| JP2009541387A5 (enExample) | ||
| NZ594369A (en) | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
| CA2508845A1 (en) | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | |
| CA2535920A1 (en) | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof | |
| JP2003508515A5 (enExample) | ||
| WO2005033279A3 (en) | Discovery of novel soluble crystalline anesthetics | |
| SE9904412D0 (sv) | Comminuted form | |
| JP2005510468A5 (enExample) | ||
| JP2007509946A5 (enExample) | ||
| EP2033637A4 (en) | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA |